1. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555-76.

2. Ezquieta B, Luzuriaga C. Neonatal salt-wasting and 11 beta-hydroxylase deficiency in a child carrying a homozygous deletion hybrid CYP11B2 (aldosterone synthase)-CYP11B1 (11 beta-hydroxylase). Clin Genet 2004;66(3):229-35.

3. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, Thomas NS, et al. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat 2003;21(6):577-81.

4. Rosler A, Leiberman E. Enzymatic defects of steroidogenesis: 11beta-hydroxylase deficiency congenital adrenal hyperplasia. In: New MI, Levine LS, editors. Adrenal diseases in childhood: pathophysiologic and clinical aspects. Basel: S. Karger; 1984. p. 47-71.

5. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency. J Endocrinol Metab 1983;56:222-229.

6. Cerame BI, Newfield RS, Pascoe L, Curnow KM, Nimkarn S, Roe TF, et al. Prenatal diagnosis and treatment of 11beta-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. J Clin Endocrinol Metab 1999;84(9):3129-34.

7. Sutherland D, Ruse J, Laidlaw J. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966;95(22): p1109-19.

8. Dluhy R, Lifton R. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999;84(12): p4341-4.

9. New MI, Peterson RE, Saenger P, Levine LS. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension. J Clin Endocrinol Metab 1976;43(6):1283-93.

10. New MI, Geller DS, Fallo F, Wilson RC. Monogenic low renin hypertension. Trends Endocrinol Metab 2005;16(3):92-7.

11. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension. J Clin Endocrinol Metab 2000;85(9):3313-8.

12. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005;90(9):5070-6.

13. New MI, Levine LS. An unidentified ACTH stimulable adrenal steroid in childhood hypertension. In: Chiumello G, Laron Z, editors. Recent progress in pediatric endocrinology; 1977; Serono Symposia: Academic Press, New York; 1977. p. 249-267.

14. Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoid excess. Trends Endocrinol Metab 2001;12(3):104-11.

15. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase--tissue specific protector of the mineralocorticoid receptor. Lancet 1988;2(8618):986-9.

16. Funder J, Pearce P, Smith R, Smith A. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242(4878): p583-5.

17. Krozowski ZS, Funder JW. Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci U S A 1983;80(19):6056-60.

18. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237(4812):268-75.

19. Quinkler M, Bappal B, Draper N, Atterbury AJ, Lavery GG, Walker EA, et al. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol 2004;217(1-2):143-9.

20. Krozowski ZS, Baker E, Obeyesekere V, Callen DF. Localization of the gene for human 11b-hydroxysteroid dehydrogenase type 2 enzyme to chromosome 16q22. Cytogenet Cell Genet 1995;71:124-125.

21. Dave-Sharma S, Wilson RC, Harbison MD, Newfield R, Razzaghy-Azar M, Krozowski Z, et al. Extensive Personal Experience: Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endo Metab 1998;83:2244-2254.

22. Palermo M, Quinkler M, Stewart PM. Apparent mineralocorticoid excess syndrome: an overview. Arq Bras Endocrinol Metabol 2004;48(5):687-96.

23. Monder C, Shackleton CH, Bradlow HL, New MI, Stoner E, Iohan F, et al. The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 1986;63(3):550-7.

24. Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 1996;45(5):605-11.

25. Wilson RC, Dave-Sharma S, Wei J, Obeyesekere VR, Li K, Ferrari P, et al. A genetic defect resulting in mild low-renin hypertension. Proc Natl Acad Sci, USA 1998;95:10200-10205.

26. Lavery G, Ronconi V, Draper N, Rabbitt E, Lyons V, Chapman K, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension 2003;42(2): p123-9.

27.New MI, Wilson RC. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci U S A 1999;96(22):12790-7.

28. Lavery GG, McTernan CL, Bain SC, Chowdhury TA, Hewison M, Stewart PM. Association studies between the HSD11B2 gene (encoding human 11beta-hydroxysteroid dehydrogenase type 2), type 1 diabetes mellitus and diabetic nephropathy. Eur J Endocrinol 2002;146(4):553-8.

29. Zaehner T, Plueshke V, Frey BM, Frey FJ, Ferrari P. Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. Kidney Int 2000;58(4):1413-9.

30. McTernan CL, Draper N, Nicholson H, Chalder SM, Driver P, Hewison M, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. J Clin Endocrinol Metab 2001;86(10):4979-83.

31. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 2001;108(9):1299-305.

32. Cushing's disease of the kidney. Lancet 1988;2(8618):1002.

33. Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation [letter]. N Engl J Med 1998;339(24):1787-8.

34. Palermo M, Delitala G, Sorba G, Cossu M, Satta R, Tedde R, et al. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome? J Endocrinol Invest 2000;23(7):457-62.

35. Riddle MC, McDaniel PA. Acute reduction of renal 11 beta-hydroxysteroid dehydrogenase activity by several antinatriuretic stimuli. Metabolism 1993;42(10):1370-4.

36. Conn J. Potassium Wasting Nephritis. Br Med J. 1954;2:1415-1416.

37. Funder JW. Editorial: aldosterone, normotension, and diastolic dysfunction. J Clin Endocrinol Metab 2005;90(9):5500-1.

38. Gordon R, Stowasser M, Tunny T, Klemm S, Finn W, Krek A. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991;18(5): p283-6.

39. Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism. Clin Exp Pharmacol Physiol 2001;28(12):1087-90.

40. Nakajin S, Shinoda M, Haniu M, Shively JE, Hall PF. C21 steroid side chain cleavage enzyme from porcine adrenal microsomes. Purification and characterization of the 17 alpha-hydroxylase/C17,20-lyase cytochrome P-450. J Biol Chem 1984;259(6):3971-6.

41. Fan YS, Sasi R, Lee C, Winter JS, Waterman MR, Lin CC. Localization of the human CYP17 gene (cytochrome P450(17 alpha)) to 10q24.3 by fluorescence in situ hybridization and simultaneous chromosome banding. Genomics 1992;14(4):1110-1.

42. Dubois R, Chappuis J. [Pheochromocytoma: pediatric features]. Arch Pediatr 1997;4(12): p1217-25.

43. Mircescu H, Wilkin F, Paquette J, Oligny LL, Decaluwe H, Gaboury L, et al. Molecular characterization of a pediatric pheochromocytoma with suspected bilateral disease. J Pediatr 2001;138(2):269-73.

44. Fonseca V, Bouloux P. Phaeochromocytoma and paraganglioma. Baillieres Clin Endocrinol Metab 1993;7(2): p509-44.

45. Ross J. Pheochromocytoma. Special considerations in children. Urol Clin North Am 2000;27(3): p393-402.

46. Khafagi FA, Shapiro B, Fischer M, Sisson JC, Hutchinson R, Beierwaltes WH. Phaeochromocytoma and functioning paraganglioma in childhood and adolescence: role of iodine 131 metaiodobenzylguanidine. Eur J Nucl Med 1991;18(3):191-8.

47. Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB, Jr., et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994;331(10):629-36.

48. Savage M, Lienhardt A, Lebrethon M, Johnston L, Huebner A, Grossman A, et al. Cushing's disease in childhood: presentation, investigation, treatment and long-term outcome. Horm Res 2001;55 Suppl 1:24-30.

49. Gomez-Sanchez C. Cushing's syndrome and hypertension. Hypertension 1986;8(3): p258-64.

50. Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 1992;43(5):409-13.

51. Cassar J, Loizou S, Kelly WF, Mashiter K, Joplin GF. Deoxycorticosterone and aldosterone excretion in Cushing's syndrome. Metabolism 1980;29(2):115-9.

52. Pirpiris M, Yeung S, Dewar E, Jennings G, Whitworth J. Hydrocortisone-induced hypertension in men. The role of cardiac output. Am J Hypertens 1993;6(4): p287-94.

53. Liddle GW, Bledsoe T, Coppage WS, Jr. A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans. Assoc. Am. Phys. 1963;76:199-213.

54. Torpy D, Stratakis C, Chrousos G. Hyper- and hypoaldosteronism. Vitam Horm 1999;57:177-216.

55. Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990;88(6): p631-7.

56. Woeber K. Thyrotoxicosis and the heart. N Engl J Med 1992;327(2): p94-8.